Inmune Bio, Inc. (INMB)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.68
- As of
Kresmion compiles this page from INMB's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Inmune Bio, Inc. (INMB): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-14.
See the full INMB dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for INMB on one page. Preview it with sample data, then open it live with a free account.
Preview the INMB dossierActive signals for INMB
- highCONSENSUS_BUY
4 tracked funds increased INMB this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +132% to INMB (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 63% of INMB (2026Q2)
- highCONSENSUS_BUY
3 tracked funds increased INMB this 2026Q2, institutional consensus
- mediumNEW_POSITION
Point72 Asset Management, L.P. new position in INMB
FREE, NO ACCOUNT
Every signal on INMB, as it fires
You are seeing 5 of 14 signals recorded on INMB since 2026-05-29.
The five above all landed on 2026-08-16. The other 9 were recorded on 4 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in INMB (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 45782T105 · 2026Q2 | $260K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 45782T105 · 2026Q2 | $173K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 45782T105 · 2026Q2 | $48K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 45782T105 · 2026Q2 | $27K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, INMB
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
INMB against its peers
INMB's operating margin of -94766.0% ranks in the 4th percentile of 12 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | INMB | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 50000 USD | 800000 USD | 22 | 15 |
| Operating margin | -94766.0% | -3536.5% | 4 | 12 |
| Net margin | -91866.0% | -3449.0% | 4 | 12 |
| Return on equity | -195.3% | -106.4% | 26 | 20 |
| 1 year | -8.2% | -53.2% | 79 | 20 |
Peers (24): SER, EXOZ, ANVS, GUTS, LONA, PDSB, ALDX, CELU, DWTX, IBIO, CRBU, ATHE, HYPD, TIL, CRVO, GOSS, CNTB, ELTX, IMA, MREO, XLO, TENX, BOLD, AURX. Left out: BSEM (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (INMB: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow INMB on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to INMB for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.